Table of Contents
Financial Highlights
Shareholder Letter
Analysis
Board of Directors
Financials
Dr. Beckman's Birthday
 

Page One | Page Two | Page Three | Page Four | Page Five | Page Six |
Page Seven | Page Eight | Page Nine | Page Ten | Page Eleven | Page Twelve

  FINANCIALS  
Back | Next 

Notes to Consolidated Financial Statements - Continued

Note 15: Earnings (Loss) Per Share
Note 16: Business Segment Information

Quarterly Information (unaudited)

Note 15: Earnings (Loss) Per Share

We compute basic and diluted earnings per share (“EPS”) in accordance with Statement of Financial Accounting Standards No. 128, “Earnings Per Share”. Basic EPS is calculated by dividing net earnings (loss) by the weighted-average common shares outstanding during the period. Diluted EPS reflects the potential dilution to basic EPS that could occur upon conversion or exercise of securities, options, or other such items, to common shares using the treasury stock method based upon the weighted-average fair value of our common shares during the period. The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations.

Years Ended December 31, 1999

Income
(Numerator)

Shares
(Denominator)

Per-Share
Amount

Basic EPS

Net earnings $106.0 28.7 $3.70
Effect of dilutive
stock options 1.0 (0.13)
Diluted EPS
Net earnings $106.0 29.7 $3.57
Year Ended Income Shares Per-Share
December 31, 1998 (Numerator) (Denominator) Amount
Basic EPS
Net earnings $ 33.5 28.0 $ 1.19
Effect of dilutive
Stock options 1.3 (0.05)
Diluted EPS
Net earnings $ 33.5 29.3 $ 1.14
Year Ended Income Shares Per-Share
December 31, 1997 (Numerator) (Denominator) Amount
Basic EPS
Net loss $(264.4) 27.6 $(9.58)
Effect of dilutive
stock options
Diluted EPS(1)
Net loss $(264.4) 27.6 $(9.58)
1)Under GAAP, as we were in a net loss position in 1997, 1.0 common share equivalents were not used to compute diluted loss per share, as the effect was antidilutive.

Back to Top

Note 16: Business Segment Information

We adopted Statement of Financial Accounting Standards No. 131, “Disclosures about Segments of an Enterprise and Related Information” (“SFAS 131”), in 1998. SFAS 131 requires segments to be determined and reported based on how management measures performance and makes decisions about allocating resources.

We are engaged primarily in the design, manufacture and sale of laboratory instrument systems and related products. Our organization has two reportable segments: (1) clinical diagnostics and (2) life science research. The clinical diagnostics segment encompasses diagnostic applications, principally in hospital laboratories. The life science research segment includes life sciences and drug discovery applications in universities, medical schools, and pharmaceutical and biotechnology companies. All corporate activities including financing transactions are captured in a central services “Center”, which is reflected in the tables below. We evaluate performance based on profit or loss from operations. Although primarily operating in the same industry, reportable segments are managed separately, since each business requires different marketing strategies and has different customers.

For the years ended December 31,

1999

1998

1997

Net sales

Clinical diagnostics $1,418.2 $1,342.5 $ 815.2
Life science research 390.5 375.7 382.8
Center
Consolidated 1,808.7 1,718.2 1,198.0
Operating income (loss)
Clinical diagnostics 260.7 172.6 (149.3)
Life science research 64.6 44.0 39.3
Center(a) (108.8) (101.8) (127.0)
Consolidated(a) 216.5 114.8 (237.0)
Interest income
Clinical diagnostics (3.6) (9.8) (2.7)
Life science research
Center (4.2) (3.6) (3.4)
Consolidated (7.8) (13.4) (6.1)
Interest expense
Clinical diagnostics
Life science research
Center 73.8 87.8 29.4
Consolidated $ 73.8 $ 87.8 $ 29.4
Total assets
Clinical diagnostics $1,460.8 $1,519.2 $1,923.1
Life science research 178.4 199.2 161.1
Center 471.6 414.9 246.8
Consolidated $2,110.8 $2,133.3 $2,331.0
Geographic areas
Sales to external customers
North America $1,003.9 $945.8 $703.0
Europe 516.6 499.8 323.3
Asia and Rest of World 288.2 272.6 171.7
Consolidated $1,808.7 $1,718.2 $1,198.0
Long-lived assets
North America $ 746.0 $ 814.7 $1,055.8
Europe 308.0 273.3 215.3
Asia and Rest of World 90.4 88.7 83.2
Consolidated $1,144.4 $1,176.7 $1,354.3
a) includes restructure (credits) charges of $(0.2) million in 1999, $19.1 million in 1998 and $59.4 million in 1997.

Back to Top

 
Quarterly Information (unaudited)
Tabular dollar amounts in millions, except amounts per share

First Quarter

Second Quarter

Third Quarter Fourth Quarter Full Year

For the years ended December 31,

1999

1998

1999

1998

1999

1998

1999

1998

1999

1998

Sales

$405.1
$399.4
$446.2
$434.7 $440.1 $400.8 $517.3 $483.3 $1,808.7 $1,718.2
Cost of sales 211.2 229.8 234.1 236.5 231.2 207.0 265.6 247.3 942.1 920.6
Gross profit 193.9 169.6 212.1 198.2 208.9 193.8 251.7 236.0 866.6 797.6
Selling, general and administrative 111.8 119.7 115.5 123.6 117.4 120.2 132.2 128.8 476.9 492.3
Research and development 38.8 41.6 42.5 42.2 42.0 41.2 50.1 46.4 173.4 171.4
Restructure charge (0.2) 19.1 (0.2) 19.1
Operating income 43.3 8.3 54.1 32.4 49.5 32.4 69.6 41.7 216.5 114.8
Earnings (loss) before income taxes 25.1 (12.4) 38.1 14.0 35.2 20.4 56.3 24.6 154.7 46.6
Net earnings (loss) $ 17.1 $ (8.4) $ 25.9 $ 9.5 $ 24.4 $ 13.9 $ 38.6 $ 18.5 $ 106.0 $ 33.5
Basic earnings
(loss) per share $ 0.60 $(0.30) $ 0.91 $ 0.34 $ 0.85 $ 0.49 $ 1.34 $ 0.65 $ 3.70 $ 1.19
Diluted earnings
(loss) per share $ 0.58 $ (0.30) $ 0.87 $ 0.32 $ 0.82 $ 0.47 $ 1.30 $ 0.63 $ 3.57 $ 1.14
Dividends per share $ 0.16 $ 0.15 $ 0.16 $ 0.15 $ 0.16 $ 0.15 $ 0.16 $ 0.16 $ 0.64 $ 0.61
Stock price — High $551/8 $607/16 $531/4 $597/16 $ 453/8 $635/8 $513/8 $541/4 $55 1/8 $63 5/8
Stock price — Low $40 $41 $437/16 $5013/16 $435/8 $50 $4015/16 $461/4 $40 $41

 

Back | Top | Next

 

 Annual Report 1999 
© 1999 Beckman Coulter, Inc. - www.beckmancoulter.com